UBS initiated coverage of Myriad Genetics (MYGN) with a Neutral rating and $18 price target The analyst believes Myriad’s growth profile has improved versus historical trends, but says GeneSight reimbursement remains a stock overhang in the near term. It continues to see growth momentum in hereditary cancer and prenatal businesses, but expects the company’s total revenue growth to normalize at high single-digits beyond 2025 versus management expectations of double-digits as tailwinds from competitors exiting the market should end by 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad announces its Prolaris test is still classified as ‘Advanced Tool’
- Leerink downgrades Myriad Genetics on reimbursement, competitive headwinds
- Myriad Genetics downgraded to Market Perform from Outperform at Leerink
- Myriad Genetics Settles Shareholder Lawsuits with Reforms
- Myriad announces Prequel Prenatal Screening can be performed at 8 weeks